Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIR study of infliximab dose reduction in IBD remission
NL-OMON44819Recruiting
- Sponsor
- Erasmus MC
- Start
- Dec 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of infliximab in inflammatory bowel disease (IBD), Crohn's disease and autoimmune colitis (2 arms), sponsored by Erasmus MC. Primary endpoint: Remission after dose adjustment. Started Dec 2014; status: recruiting.
02
Drugs
infliximab
03
Conditions
inflammatory bowel disease (IBD)Crohn's diseaseautoimmune colitis
Beyond the preview
Go deeper on NL-OMON44819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44819.